- Home
- CASS vs REPL Comparison
CASS vs REPL Comparison
Compare CASS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASS
- REPL
- Stock Information
- Founded
- CASS 1906
- REPL 2015
- Country
- CASS United States
- REPL United States
- Employees
- CASS N/A
- REPL N/A
- Industry
- CASS Business Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- CASS Consumer Discretionary
- REPL Health Care
- Exchange
- CASS Nasdaq
- REPL Nasdaq
- Market Cap
- CASS 586.3M
- REPL 578.4M
- IPO Year
- CASS 1996
- REPL 2018
- Fundamental
- Price
- CASS $42.27
- REPL $7.91
- Analyst Decision
- CASS Buy
- REPL Strong Buy
- Analyst Count
- CASS 1
- REPL 6
- Target Price
- CASS $46.00
- REPL $20.00
- AVG Volume (30 Days)
- CASS 58.5K
- REPL 1.1M
- Earning Date
- CASS 04-17-2025
- REPL 05-19-2025
- Dividend Yield
- CASS 2.91%
- REPL N/A
- EPS Growth
- CASS N/A
- REPL N/A
- EPS
- CASS 1.53
- REPL N/A
- Revenue
- CASS $220,944,000.00
- REPL N/A
- Revenue This Year
- CASS N/A
- REPL $31.16
- Revenue Next Year
- CASS $7.19
- REPL N/A
- P/E Ratio
- CASS $27.66
- REPL N/A
- Revenue Growth
- CASS 2.32
- REPL N/A
- 52 Week Low
- CASS $37.99
- REPL $4.92
- 52 Week High
- CASS $47.14
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- CASS 61.21
- REPL 39.63
- Support Level
- CASS $41.04
- REPL $9.01
- Resistance Level
- CASS $42.79
- REPL $10.30
- Average True Range (ATR)
- CASS 0.89
- REPL 0.77
- MACD
- CASS 0.31
- REPL -0.04
- Stochastic Oscillator
- CASS 96.35
- REPL 24.93
About CASS Cass Information Systems Inc
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. It operates in two segments: Information Services and Banking Services. The firm generates maximum revenue from the Information Services segment.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.